|||When compared to conventional beta-blocking agents, which lack additional vasodilating activity, carvedilol causes a smaller reduction in the resting heart rate. Myocardial function is therefore maintained, as well as peripheral blood flow.|
|||Carvedilol has little or no effect on serum electrolytes, cholesterol, triglycerides, high density lipoproteins or low density lipoproteins, and although the plasma renin activity is reduced significantly, renal function is not affected.|
|-||Treatment of mild to moderate essential hypertension.|
|-||Treatment of mild to moderate stable symptomatic heart failure of ischemic or cardiomyopathic origin often in conjunction with standard therapy. Carvedilol has previously been used in patients unable to tolerate an ACE inhibitor and also in those not receiving digitalis.|
|Caution should be exercised when transferring a patient from clonidine. The withdrawal of clonidine may result in the release of large amounts of catecholamines which may give rise to a hypertensive crisis. If beta-blockers are administered in these circumstances, the unopposed alpha receptor stimulation may potentiate this effect.|
If a beta-blocker and clonidine are given concurrently, the clonidine should not be discontinued until several days after the withdrawal of the beta-blocker, as severe rebound hypertension may occur.
It can be dangerous to administer this medicine concomitantly with the following medicines: hypoglycaemic agents (see "Precautions"), phenothiazines and various anti-arrhythmic agents (see below). Such drug-drug interactions can have life-threatening consequences.
Digitalisation of patients receiving long-term beta-blocking therapy may be necessary if congestive, cardiac failure is likely to develop. This combination may be considered despite the potentiation of negative chronotropic effects of the two medicines. Careful control of the dosages and of the individual patient's response (and notably pulse rate), is essential in this situation.
|CARLOC 12.5:||Cream coloured, circular, biconvex tablets with cross break-line on one side and plain on the ether.|
|CARLOC 25:||Light red coloured, circular biconvex tablets with cross break-line on one side and plain on the other.|
|CARLOC 12.5:||30 or 60 tablets per pack in blister strips of 10 tablets.|
|CARLOC 25:||30 or 60 tablets per pack in blister strips of 10 tablets.|